Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
17. Mai 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
12. Mai 2022 07:30 ET
|
Xilio Therapeutics, Inc.
Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for...
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
07. April 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
01. März 2022 06:30 ET
|
Xilio Therapeutics, Inc.
Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with Plans to Submit IND for XTX301 in Second Half of 2022 Continue to Anticipate Cash Runway...
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
28. Februar 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
03. Februar 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
20. Januar 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with...
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
06. Januar 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
02. Dezember 2021 07:30 ET
|
Xilio Therapeutics, Inc.
Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4...
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
12. November 2021 07:00 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today...